What's in Marie Hudson, MD's pipeline?

Marie Hudson, MD has 3 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 3 in Phase 1.

Which companies overlap with Marie Hudson, MD's portfolio?

Top competitors by shared drug class: A. Vogel AG, Bausch & Lomb Incorporated, Organon and Co, Panacea Biotec Ltd, Prof. Dr. Stephan Weidinger.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/marie-hudson-md.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Marie Hudson, MD — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Marie Hudson, MD pipeline: 0 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

A. Vogel AG · 1 shared drug class
Bausch & Lomb Incorporated · 1 shared drug class
Organon and Co · 1 shared drug class
Panacea Biotec Ltd · 1 shared drug class
Prof. Dr. Stephan Weidinger · 1 shared drug class
Salus Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Marie Hudson, MD:

Cite this brief

Drug Landscape (2026). Marie Hudson, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/marie-hudson-md. Accessed 2026-05-18.